Current Cancer Drug Targets

Ruiwen Zhang 
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106
USA

Back

Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies

Author(s): K. Podar, K. C. Anderson.

Abstract:

Research on the formation of new blood vessels (angiogenesis) in general and vascular endothelial growth factor (VEGF) in particular is a major focus in biomedicine and has led to the clinical approval of the monoclonal anti- VEGF antibody bevazicumab; and the second-generation multitargeted receptor kinase inhibitors (RTKIs) sorafenib, sunitinib, and pazopanib. Although these agents show significant preclinical and clinical anti-cancer activity, they prolong overall survival of cancer patients for only months, followed by a restoration of tumor growth and progression. Therefore, there is a clear need to increase our understanding of tumor angiogenesis and the development of resistance. In this review we discuss up-to-date knowledge on mechanisms of tumor angiogenesis, and summarize preclinical and clinical data on existing and potential future anti-angiogenic agents and treatment strategies for Multiple Myeloma (MM) and other hematologic and solid malignancies.

Keywords: AMG-386, AVE8062, axitinib, bevacizumab, CDP860, CE-245677, CEP-11981, cilengitide, combretastatin, CP-868, 596, enzastaurin, exherin, HuMV833, lenalidomide, metronomic chemotherapy, MN-029, OMP-21M18, pazopanib, PF-4856884, pomalidomide, Reg421, semaxanib, sorafenib and sunitinib, TB403, thalidomide, TZT-1027, vadimezan, vandetanib, vatalanib, VEGFR antibodies, VEGF-trap, ZD6126

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 11
ISSUE: 9
Year: 2011
Page: [1005 - 1024]
Pages: 20
DOI: 10.2174/156800911798073113
Price: $58